CPI-360 is primarily utilized in the field of medicinal chemistry and drug development, particularly in the study and treatment of cancer. It functions as a potent and selective inhibitor of the BET (Bromodomain and Extra-Terminal) family of proteins, which play a critical role in regulating gene expression. By inhibiting BET proteins, CPI-360 disrupts the transcription of oncogenes, thereby halting the proliferation of cancer cells. This makes it a valuable tool in preclinical research for understanding the mechanisms of BET inhibition and its potential therapeutic applications. Additionally, CPI-360 is used to explore combination therapies, where it may enhance the efficacy of other anticancer agents. Its specificity and effectiveness in targeting BET proteins have positioned it as a promising candidate for the development of novel cancer treatments.